Respiratory syncytial virus can cause serious lower-respiratory illness, especially in young infants and some children with increased risk. Current guidance provides two main ways to protect most infants: maternal RSV vaccination during pregnancy or a long-acting RSV monoclonal antibody given to the infant. Most infants do not need both.
Current federal guidance describes nirsevimab and clesrovimab as long-acting infant antibody products. These products provide antibodies directly; they are not vaccines. Nirsevimab is also recommended for certain children ages 8–19 months entering a second RSV season who are at increased risk.
Eligibility and timing depend on age, season, maternal vaccination, medical history, product guidance, and availability. Ask Sapphire what the practice currently stocks, whether an appointment is available, and how insurance may process the product. Coverage cannot be guaranteed.